In Q1 FY2026, Assembly Biosciences reported revenue of $8.2 million, down 12.8% year-over-year. Net loss was $9.1 million, slightly worse than the prior year. Operating loss widened to $11.4 million. Diluted EPS improved to -$0.54 from -$1.17. Cash stood at $31.1 million, and equity was $198.6 million.
•Revenue decreased 12.8% YoY to $8.2 million.
•Net loss of $9.1 million, 3% worse than prior year.
•Diluted EPS improved to -$0.54 from -$1.17.
•Cash and equivalents of $31.1 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Assembly Biosciences, Inc., a biotechnology company develops therapeutic candidates for the treatment of viral diseases globally. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
It also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection
ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the R&D of virology therapies. Incorporated in 2005 and headquartered in South San Francisco, California, Assembly Biosciences was formerly known as Ventrus Biosciences, Inc. before rebranding in June 2014.
Assembly Biosciences, Inc. is a biotechnology company focused on developing therapeutic candidates for the treatment of viral diseases globally. Its pipeline includes long-acting helicase-primase inhibitors such as ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes. The company also develops ABI-6250, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor in Phase 1a for chronic HDV infection, and ABI-4334, an orally bioavailable next-generation capsid assembly modulator in Phase 1b for chronic hepatitis B virus (HBV) infection. Additionally, ABI-7272 is an oral broad-spectrum NNPI for transplant-associated herpesviruses. Assembly Biosciences has an option, license, and collaboration agreement with Gilead Sciences for virology therapies.
Where is Assembly Biosciences (ASMB) listed and what currency does it trade in?
Assembly Biosciences is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ASMB. Its shares are traded in United States Dollars (USD). The company is headquartered in South San Francisco, California, and operates primarily in the United States, though its research and development efforts target viral diseases globally.
What sector and industry does Assembly Biosciences (ASMB) belong to?
Assembly Biosciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies for viral diseases, including herpes, hepatitis B, hepatitis delta, and transplant-associated herpesviruses. The company's work involves advanced drug discovery and clinical development, positioning it within the broader biotech landscape that aims to address unmet medical needs in infectious diseases.
Where is Assembly Biosciences (ASMB) headquartered and what is its history?
Assembly Biosciences is headquartered in South San Francisco, California, United States. The company was incorporated in 2005 and was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences in June 2014. Its operations are centered in the U.S., but its therapeutic candidates are developed for global markets, targeting viral infections that affect patients worldwide. The company's location in the San Francisco Bay Area places it within a major biotechnology hub, facilitating collaboration and access to talent.
What are the key pipeline products of Assembly Biosciences (ASMB)?
Assembly Biosciences' pipeline includes several key candidates for viral diseases. For recurrent genital herpes, it has ABI-5366 and ABI-1179, both long-acting helicase-primase inhibitors in Phase 1 studies. For chronic hepatitis delta virus (HDV) infection, ABI-6250 is an orally bioavailable entry inhibitor in Phase 1a. For chronic hepatitis B virus (HBV), ABI-4334 is an orally bioavailable next-generation capsid assembly modulator in Phase 1b. Additionally, ABI-7272 is an oral broad-spectrum NNPI for transplant-associated herpesviruses. The company also has a collaboration with Gilead Sciences for virology therapies, which may expand its pipeline further.